Docoh
Loading...

47 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
or in the aggregate result in a Material Adverse Change; and the Company is not aware of any pending investigation which might lead to such a claim. (y … , hearing, enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product operation
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
, there is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil … ) There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, study sites … to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether … that this representation is made (j) Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending
8-K
EX-10.2
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within … with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
Adverse Effect; and the Company is not aware of any pending investigation which might lead to such a claim. Neither the Company nor its subsidiary … of any pending or, to the knowledge of Company, threatened, investigation by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could … impact our reputation and brand and expose us to increased risks of governmental investigation, litigation and other liability, any of which could
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which … and expose us to increased risks of governmental investigation, litigation and other liability, any of which could adversely affect our business
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business … of governmental investigation, litigation and other liability, any of which could adversely affect our business. Furthermore, responding to such an attack
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of the Company Disclosure Letter. (b) The Company has no actual knowledge, without any investigation, that the Company is infringing upon … [www.promettherapeutics.com]. Without any special investigation for purposes of this Agreement, the Company, in its reasoned judgment, has determined that making, using
S-1/A
EX-3.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
to be indemnified, the Indemnitee must notify the Corporation in writing as soon as practicable of any action, suit, proceeding or investigation involving … such Indemnitee for which indemnity will or could be sought. With respect to any action, suit, proceeding or investigation of which the Corporation is so
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
is not aware of any pending investigation which might lead to such a claim. Neither the Company nor its subsidiary anticipate incurring any material … of Company, threatened, investigation by the FDA pursuant to its “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” Final
S-1/A
EX-3.2
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
hereunder. (e) There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation … , subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Processa
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry, or investigation of any nature, civil, criminal, regulatory, or otherwise … , subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Processa
S-1/A
EX-10.12
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
by or as a result of any information furnished to, or any investigation made by or knowledge of, Yuhan or its representatives. 12. Miscellaneous
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
hereunder. (e) There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation … , subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Processa
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry, or investigation of any nature, civil, criminal, regulatory, or otherwise, in law … , subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Processa
8-K
EX-10.2
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
by or as a result of any information furnished to, or any investigation made by or knowledge of, Yuhan or its representatives. 12. Miscellaneous. 12.1
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices … to increased risks of governmental investigation, litigation and other liability, any of which could adversely affect our business. Furthermore